Chengdu Kanghong Pharmaceutical Group Future Growth
Future criteria checks 1/6
Chengdu Kanghong Pharmaceutical Group is forecast to grow earnings and revenue by 13.4% and 10.3% per annum respectively. EPS is expected to grow by 13.4% per annum. Return on equity is forecast to be 13.4% in 3 years.
Key information
13.4%
Earnings growth rate
13.4%
EPS growth rate
Pharmaceuticals earnings growth | 18.7% |
Revenue growth rate | 10.3% |
Future return on equity | 13.4% |
Analyst coverage | Low |
Last updated | 31 Aug 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 5,558 | 1,606 | N/A | 1,806 | 1 |
12/31/2025 | 5,115 | 1,446 | N/A | 1,538 | 1 |
12/31/2024 | 4,648 | 1,247 | N/A | 1,470 | 1 |
9/30/2024 | 4,370 | 1,193 | 1,314 | 1,467 | N/A |
6/30/2024 | 4,331 | 1,212 | 1,336 | 1,468 | N/A |
3/31/2024 | 4,165 | 1,139 | 1,300 | 1,437 | N/A |
12/31/2023 | 3,957 | 1,045 | 1,080 | 1,218 | N/A |
9/30/2023 | 3,756 | 967 | 948 | 1,117 | N/A |
6/30/2023 | 3,546 | 885 | 820 | 1,038 | N/A |
3/31/2023 | 3,379 | 879 | 528 | 824 | N/A |
1/1/2023 | 3,389 | 897 | 570 | 925 | N/A |
9/30/2022 | 3,392 | 523 | 446 | 876 | N/A |
6/30/2022 | 3,469 | 538 | 311 | 808 | N/A |
3/31/2022 | 3,586 | 485 | 91 | 588 | N/A |
1/1/2022 | 3,605 | 421 | -75 | 494 | N/A |
9/30/2021 | 3,792 | -196 | -96 | 83 | N/A |
6/30/2021 | 3,802 | -184 | -210 | 174 | N/A |
3/31/2021 | 3,577 | -213 | -145 | 433 | N/A |
12/31/2020 | 3,295 | -270 | -349 | 273 | N/A |
9/30/2020 | 3,196 | 745 | -271 | 898 | N/A |
6/30/2020 | 3,132 | 712 | -323 | 801 | N/A |
3/31/2020 | 3,173 | 684 | -269 | 770 | N/A |
12/31/2019 | 3,257 | 718 | -151 | 812 | N/A |
9/30/2019 | 3,145 | 741 | -113 | 683 | N/A |
6/30/2019 | 3,053 | 725 | -203 | 450 | N/A |
3/31/2019 | 2,934 | 700 | -107 | 415 | N/A |
12/31/2018 | 2,917 | 695 | -108 | 351 | N/A |
9/30/2018 | 2,870 | 735 | -45 | 466 | N/A |
6/30/2018 | 2,801 | 721 | N/A | 595 | N/A |
3/31/2018 | 2,844 | 699 | N/A | 709 | N/A |
12/31/2017 | 2,786 | 644 | N/A | 767 | N/A |
9/30/2017 | 2,809 | 602 | N/A | 884 | N/A |
6/30/2017 | 2,745 | 552 | N/A | 1,028 | N/A |
3/31/2017 | 2,658 | 546 | N/A | 978 | N/A |
12/31/2016 | 2,540 | 497 | N/A | 846 | N/A |
9/30/2016 | 2,434 | 455 | N/A | 800 | N/A |
6/30/2016 | 2,348 | 444 | N/A | 579 | N/A |
3/31/2016 | 2,197 | 428 | N/A | 573 | N/A |
12/31/2015 | 2,074 | 394 | N/A | 482 | N/A |
9/30/2015 | 2,016 | 352 | N/A | 415 | N/A |
6/30/2015 | 1,865 | 315 | N/A | 402 | N/A |
3/31/2015 | 1,771 | 286 | N/A | N/A | N/A |
12/31/2014 | 1,675 | 273 | N/A | 291 | N/A |
12/31/2013 | 1,477 | 316 | N/A | 333 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 002773's forecast earnings growth (13.4% per year) is above the savings rate (2.8%).
Earnings vs Market: 002773's earnings (13.4% per year) are forecast to grow slower than the CN market (26.3% per year).
High Growth Earnings: 002773's earnings are forecast to grow, but not significantly.
Revenue vs Market: 002773's revenue (10.3% per year) is forecast to grow slower than the CN market (13.9% per year).
High Growth Revenue: 002773's revenue (10.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 002773's Return on Equity is forecast to be low in 3 years time (13.4%).